Literature DB >> 17872384

Genetics of hypercalciuric nephrolithiasis: renal stone disease.

Michael J Stechman1, Nellie Y Loh, Rajesh V Thakker.   

Abstract

Renal stone disease (nephrolithiasis) affects 5% of adults and is often associated with hypercalciuria. Hypercalciuric nephrolithiasis is a familial disorder in more than 35% of patients, and may occur as a monogenic disorder, or as a polygenic trait involving 3 to 5 susceptibility loci in man and rat, respectively. Studies of monogenic forms of hypercalciuric nephrolithiasis in man, for example, Bartter syndrome, Dent's disease, autosomal dominant hypocalcemic hypercalciuria (ADHH), hypercalciuric nephrolithiasis with hypophosphatemia, and familial hypomagnesemia with hypercalciuria have helped to identify a number of transporters, channels, and receptors that are involved in regulating the renal tubular reabsorption of calcium. Thus, Bartter syndrome, an autosomal recessive disease, is caused by mutations of the bumetanide-sensitive Na-K-Cl (NKCC2) cotransporter, the renal outer-medullary potassium channel (ROMK), the voltage-gated chloride channel, CLC-Kb, or in its beta subunit, Barttin. Dent's disease, an X-linked disorder characterized by low molecular weight proteinuria, hypercalciuria, and nephrolithiasis, is due to mutations of the chloride/proton antiporter, CLC-5; ADHH is associated with activating mutations of the calcium-sensing receptor, which is a G protein-coupled receptor; hypophosphatemic hypercalciuric nephrolithiasis associated with rickets is due to mutations in the type 2c sodium-phosphate cotransporter (NPT2c); and familial hypomagnesemia with hypercalciuria is due to mutations of paracellin-1, which is a member of the claudin family of membrane proteins that form the intercellular tight junction barrier in a variety of epithelia. These studies have provided valuable insights into the renal tubular pathways that regulate calcium reabsorption and predispose to kidney stones and bone disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872384     DOI: 10.1196/annals.1402.030

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density.

Authors:  Gudmar Thorleifsson; Hilma Holm; Vidar Edvardsson; G Bragi Walters; Unnur Styrkarsdottir; Daniel F Gudbjartsson; Patrick Sulem; Bjarni V Halldorsson; Femmie de Vegt; Frank C H d'Ancona; Martin den Heijer; Leifur Franzson; Claus Christiansen; Peter Alexandersen; Thorunn Rafnar; Kristleifur Kristjansson; Gunnar Sigurdsson; Lambertus A Kiemeney; Magnus Bodvarsson; Olafur S Indridason; Runolfur Palsson; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

2.  Gene panel sequencing identifies a likely monogenic cause in 7% of 235 Pakistani families with nephrolithiasis.

Authors:  Ali Amar; Amar J Majmundar; Ihsan Ullah; Ayesha Afzal; Daniela A Braun; Shirlee Shril; Ankana Daga; Tilman Jobst-Schwan; Mumtaz Ahmad; John A Sayer; Heon Yung Gee; Jan Halbritter; Thomas Knöpfel; Nati Hernando; Andreas Werner; Carsten Wagner; Shagufta Khaliq; Friedhelm Hildebrandt
Journal:  Hum Genet       Date:  2019-02-18       Impact factor: 4.132

Review 3.  Epidemiology of stone disease across the world.

Authors:  Igor Sorokin; Charalampos Mamoulakis; Katsuhito Miyazawa; Allen Rodgers; Jamsheer Talati; Yair Lotan
Journal:  World J Urol       Date:  2017-02-17       Impact factor: 4.226

4.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

5.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 6.  Urolithiasis as an extraarticular manifestation of ankylosing spondylitis.

Authors:  Cengiz Korkmaz; Döndü Üsküdar Cansu; John A Sayer
Journal:  Rheumatol Int       Date:  2017-08-18       Impact factor: 2.631

Review 7.  Genetic determinants of urolithiasis.

Authors:  Carla G Monico; Dawn S Milliner
Journal:  Nat Rev Nephrol       Date:  2011-12-20       Impact factor: 28.314

8.  1,25-(OH)2D-24 Hydroxylase (CYP24A1) Deficiency as a Cause of Nephrolithiasis.

Authors:  Galina Nesterova; May Christine Malicdan; Kaori Yasuda; Toshiyuki Sakaki; Thierry Vilboux; Carla Ciccone; Ronald Horst; Yan Huang; Gretchen Golas; Wendy Introne; Marjan Huizing; David Adams; Cornelius F Boerkoel; Michael T Collins; William A Gahl
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

9.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

10.  Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Authors:  Kevin K Frick; John R Asplin; Murray J Favus; Christopher Culbertson; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.